David Lechuga is a seasoned pharmaceutical scientist with over twenty-five years of industrial experience, currently serving as the Principal Scientist at Pearl Therapeutics. In this pivotal role, he leads the Pharmaceutical Sciences Department, where he spearheads innovative projects aimed at revolutionizing the delivery mechanisms for...
David Lechuga is a seasoned pharmaceutical scientist with over twenty-five years of industrial experience, currently serving as the Principal Scientist at Pearl Therapeutics. In this pivotal role, he leads the Pharmaceutical Sciences Department, where he spearheads innovative projects aimed at revolutionizing the delivery mechanisms for inhalable therapeutic agents, specifically targeting asthma and chronic obstructive pulmonary disease (COPD). His expertise in drug development encompasses a diverse range of disciplines, including material sciences, biodistribution, and the characterization of complex drug formulations.
One of David's key projects involves the development of novel formulation technologies that utilize cosuspensions of spray-dried, low-density, propellant-insoluble particles combined with micronized active pharmaceutical ingredients (APIs). This cutting-edge approach leverages off-the-shelf pressurized metered-dose inhalers, enhancing the efficacy and patient compliance of inhalable therapies. His work not only emphasizes the importance of Chemistry, Manufacturing, and Controls (CMC) but also aligns with current Good Manufacturing Practices (cGMP), ensuring that all formulations meet stringent regulatory standards.
David's extensive background in nanomedicines, including PEGylated drugs and liposomal formulations, positions him as a thought leader in the field. His proficiency in materials science and characterization techniques further enriches his contributions to the development of small molecules and vaccines. By integrating his vast knowledge with a focus on clinical trials and R&D, David continues to drive forward the mission of Pearl Therapeutics, ultimately aiming to improve the quality of life for patients suffering from respiratory diseases.
